TrialSignal
Clinical trial intelligence report
Towards the Most Accurate Diagnosis and Monitoring of Complement-mediated Rare Kidney Diseases
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT05985122
Status
ACTIVE_NOT_RECRUITING
Phase
NA
Sponsor
Mario Negri Institute for Pharmacological Research
Executive brief
Investment-Ready Snapshot
The COMPRare project aims to develop new diagnostic tools for aHUS and C3G, improving patient stratification and treatment monitoring. Funded by the EJP RD program of the EU, it involves a consortium of seven European institutions. The study focuses on identifying biomarkers and standardizing assays to enhance diagnosis and treatment options for these ultra-rare conditions.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05985122
Indication
Hemolytic-Uremic Syndrome
Modality
RNA therapy
Target
Complement-mediated Rare Kidney Diseases (aHUS and C3G)
Intervention
C3NEF assay
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.